# A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors

Source: https://onco.cc/trials/nct06150885/  
OnCo record `nct06150885` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HLA-G-CAR.BiTE allogeneic γδ T cells in advanced solid tumours, run by Ever Supreme Bio Technology Co., Ltd., now recruiting.

## Summary

A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT06150885 by Ever Supreme Bio Technology Co., Ltd., with 60 participants planned, started 2024-09-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: HLA-G-CAR.BiTE allogeneic γδ T cells.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06150885
- Phase: 1/2
- Setting: A Single Arm, Open Label, Dose-escalation Phase I and Dose-expansion Phase IIa Clinical Study to Evaluate the Feasibility, Safety, and Efficacy of Allogeneic Chimeric Antigen Receptor (CAR) Gamma-Delta T Cells CAR001 in Subjects With Relapsed/Refractory Solid Tumors
- Sponsor: Ever Supreme Bio Technology Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06150885: https://clinicaltrials.gov/study/NCT06150885

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06150885.json